158 related articles for article (PubMed ID: 24145180)
1. Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers.
Celik B; Yalcin AD; Bisgin A; Dimitrakopoulou-Strauss A; Kargi A; Strauss LG
Med Sci Monit; 2013 Oct; 19():875-82. PubMed ID: 24145180
[TBL] [Abstract][Full Text] [Related]
2. Blood eosinophil and platelet levels, proteomics patterns of trail and CXCL8 correlated with survival in bevacizumab treated metastatic colon cancers.
Yalcin AD; Kargi A; Gumuslu S
Clin Lab; 2014; 60(2):339-40. PubMed ID: 24660552
[TBL] [Abstract][Full Text] [Related]
3. Erratum to "IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer" [Clin. Lab. 2012; 58:501-505].
Kargi A; Yalcin AD; Erin N; Savas B; Polat HH; Gorczynski RM
Clin Lab; 2012; 58(9-10):1103-7. PubMed ID: 23163132
[TBL] [Abstract][Full Text] [Related]
4. IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer.
Kargi A; Yalcin AD; Erin N; Savas B; Polat HH; Gorczynski RM
Clin Lab; 2012; 58(5-6):501-5. PubMed ID: 22783581
[TBL] [Abstract][Full Text] [Related]
5. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.
Bisgin A; Kargi A; Yalcin AD; Aydin C; Ekinci D; Savas B; Sanlioglu S
BMC Cancer; 2012 Feb; 12():58. PubMed ID: 22313795
[TBL] [Abstract][Full Text] [Related]
6. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
7. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Pöttgen C; Levegrün S; Theegarten D; Marnitz S; Grehl S; Pink R; Eberhardt W; Stamatis G; Gauler T; Antoch G; Bockisch A; Stuschke M
Clin Cancer Res; 2006 Jan; 12(1):97-106. PubMed ID: 16397030
[TBL] [Abstract][Full Text] [Related]
8. Ferret thoracic anatomy by 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging.
Wu A; Zheng H; Kraenzle J; Biller A; Vanover CD; Proctor M; Sherwood L; Steffen M; Ng C; Mollura DJ; Jonsson CB
ILAR J; 2012; 53(1):E9-21. PubMed ID: 23382267
[TBL] [Abstract][Full Text] [Related]
9. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
[TBL] [Abstract][Full Text] [Related]
10. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
[TBL] [Abstract][Full Text] [Related]
11. Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.
Miyazaki Y; Nawa Y; Miyagawa M; Kohashi S; Nakase K; Yasukawa M; Hara M
Ann Hematol; 2013 Jan; 92(2):239-44. PubMed ID: 23079891
[TBL] [Abstract][Full Text] [Related]
12. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
13. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
[TBL] [Abstract][Full Text] [Related]
14. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.
Ikushima H; Dong L; Erasmus J; Allen P; McAleer MF; Zhuang Y; Sasaki R; Komaki R
J Radiat Res; 2010; 51(4):465-71. PubMed ID: 20508373
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.
Shum WY; Hsieh TC; Yeh JJ; Chen JH; Su CC; Liang JA; Kao CH
Eur J Radiol; 2012 May; 81(5):1024-8. PubMed ID: 21458941
[TBL] [Abstract][Full Text] [Related]
17. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
20. Is there a correlation between 18F-FDG-PET standardized uptake value, T-classification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck?
Haerle SK; Huber GF; Hany TF; Ahmad N; Schmid DT
Eur Arch Otorhinolaryngol; 2010 Oct; 267(10):1635-40. PubMed ID: 20680640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
